We employ and extensively characterise an ex vivo culture system to study terminal erythroid maturation of CD34 + progenitors from the peripheral blood of normal individuals and patients with Congenital Dyserythropoietic Anaemia type 1 (CDA-I). Using morphological analysis, FACS analysis and the proteomic approach CyTOF, we analysed patient-derived erythroblasts stage-matched with those from healthy donors during the expansion phase and into early differentiation. In patient cells, aspects of disordered erythropoiesis manifest midway through differentiation, including increased proliferation and changes in the DNA accessibility profile. We also show that cultured erythroblasts from CDA-I patients recapitulate the pathognomic feature of this erythroid disorder with up to 40% of the cells having abnormal 'spongy' chromatin morphology by electron microscopy, as well as upregulation of GDF15, a marker of ineffective erythropoiesis. In the tertiary phase of culture, patient cells show significantly less enucleation and there is persistence of earlier erythroid precursors. Furthermore, the enucleation defect appears to be more severe in patients with mutations in C15orf41, as compared to the other known causative gene CDAN1, indicating a genotype/phenotype correlation in CDA-I. Such erythroblasts are a valuable resource for investigating the pathogenesis of this disease and provide the opportunity for streamlining diagnosis for CDA-I patients and ultimately other forms of unexplained anaemia.
Abstract:
We employ and extensively characterise an ex vivo culture system to study terminal erythroid maturation of CD34 + progenitors from the peripheral blood of normal individuals and patients with Congenital Dyserythropoietic Anaemia type 1 (CDA-I). Using morphological analysis, FACS analysis and the proteomic approach CyTOF, we analysed patient-derived erythroblasts stage-matched with those from healthy donors during the expansion phase and into early differentiation. In patient cells, aspects of disordered erythropoiesis manifest midway through differentiation, including increased proliferation and changes in the DNA accessibility profile. We also show that cultured erythroblasts from CDA-I patients recapitulate the pathognomic feature of this erythroid disorder with up to 40% of the cells having abnormal 'spongy' chromatin morphology by electron microscopy, as well as upregulation of GDF15, a marker of ineffective erythropoiesis. In the tertiary phase of culture, patient cells show significantly less enucleation and there is persistence of earlier erythroid precursors. Furthermore, the enucleation defect appears to be more severe in patients with mutations in C15orf41, as compared to the other known causative gene CDAN1, indicating a genotype/phenotype correlation in CDA-I. Such erythroblasts are a valuable resource for investigating the pathogenesis of this disease and provide the opportunity for streamlining diagnosis for CDA-I patients and ultimately other forms of unexplained anaemia.
Introduction:
Congenital dyserythropoietic anaemia type 1 (CDA-I) is an autosomal recessive disease associated with characteristic abnormalities in erythroblast nuclei, including binucleate cells and inter-nuclear bridging. 1 There is ineffective erythropoiesis and macrocytic anaemia, commonly mild to moderate although some patients are transfusion-dependent and the disease can be fatal. A diagnostic feature of CDA-I is the "Swiss-cheese" or spongy pattern of abnormal chromatin in u p t o 5 0 % o f erythroblasts obtained from bone marrow aspirates, visualised using transmission electron microscopy (TEM). 2 In ~90% of cases, bi-allelic mutations in one of two genes, CDAN1 (encoding Codanin-1) or C15orf41 are causative, 3, 4 with the genetic causes of the remaining ~10% of patients yet to be determined. The observation that Codanin-1 and C15orf41 both directly interact with the histone chaperone ASF1 5, 6 implies that the two genes participate in the same pathway. Studies in non-erythroid cells have provided insight into protein function, identifying cell-cycle regulation of CDAN1 3, 7 and a potential role in histone supply to the nucleus. 5 However CDA-I is predominantly an erythroid-restricted disease, and use of erythroblasts for functional analysis would be the most informative way to study CDA-I aetiology and may shed light on how loss-of-function and a range of missense mutations in either gene produces a common erythroid phenotype. Furthermore, as novel C15orf41 or CDAN1 variants are identified, pathogenicity cannot be determined without additional diagnostic evidence specific to CDA-I. Availability of cultured erythroblasts for such analysis would avoid the need to perform invasive bone marrow aspirates, particularly important for paediatric patients.
Ex vivo systems that closely recapitulate the in vivo state provide an important path to understanding the basis of human disease. The expansion and differentiation of CD34 + haematopoietic stem cells obtained from peripheral blood has been successfully used to study normal erythropoiesis [8] [9] [10] [11] and to elucidate disease mechanisms in a number of erythroid disorders including Diamond Blackfan Anaemia (DBA) 12, 13 and myelodysplastic syndrome (MDS). 9 To fully understand the defects that arise in patients who do not generate sufficient mature, lineagespecific cells, any culture system used must recapitulate the terminal stages of erythropoiesis through to enucleation. Furthermore, whilst erythroid culture systems can yield large numbers of erythroblasts for downstream analyses, it has become clear that careful attention must be paid to stage-match diseased and healthy erythroblasts, to ensure findings can be correctly interpreted. 14 Here we use an ex vivo three-phase culture system 8 (broadly consisting of expansion, differentiation and enucleation) whereby CD34 + cells obtained from peripheral blood from both healthy donors and patients with TEM-proven CDA-I are successfully differentiated into reticulocytes. By monitoring differentiating erythroblasts using immunophenotyping by FACS (fluorescence activated cell sorting), morphological assessment, CyTOF (mass cytometry time of flight) and ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing), we ensure that equivalently staged cell populations are compared. We find patient and healthy erythroblasts comparable during expansion, however, as differentiation proceeds, differences in proliferation rate and alterations in the DNA accessibility profile become apparent. Crucially, at this stage, the pathognomic feature of spongy heterochromatin is recapitulated using this culture system.
During the enucleation phase, defects in patient erythroblasts become further evident, with a reduction in enucleation, persistence of precursors and reduced Band 3 expression.
This work shows that appropriate culturing of CD34 + erythroid progenitors alongside careful stage-matching of differentiating cells furthers our understanding of CDA-I, and potentially other anaemias that result from ineffective erythropoiesis.
Our findings also indicate that such ex vivo culturing can be used as a less invasive means to diagnose CDA-I in patients with novel gene variants. Supplemental Tables are available from the authors. Study approval, consent and ethics: Subjects were identified through physicianinitiated referral through the Oxford Molecular Diagnostic Centre where next generation sequencing was conducted to determine the cause of the patients' anaemia. Where patients with a molecular diagnosis of CDA-I were identified, patient consent was obtained for entry into this research study. This study was approved by the Wales Research Ethics Committee (REC5) (13/WA/0371) with written consent from patients and/or parents for any samples obtained. Table 1 ) and with Hoechst-33258 (ThermoFisher) for live/dead analysis. FACS was carried out on an Attune NxT (ThermoFisher), voltages and compensation were set using Ultra Comp eBeads (ThermoFisher) for antibodies and single stained cells for dyes. Gating was performed using fluorescenceminus-one (FMO) controls (see Supplemental Fig 1) . Analysis was performed using FlowJo (v10.4.2). At day 17 enucleation was assessed both by counting the different erythroid subtypes on cytospins and by incubating 1-3x10 5 cultured erythroblasts with 0.5 µl of 2.5 mg ml -1 Hoechst-33342 (ThermoFisher) for 45 minutes at 37 o C. FACS then established the number of enucleated cells based on DNA content (Hoechst) and cell size (Supplemental Fig 6A) .
Methods:

Isolation of CD34
Transmission
Electron Microscopy: Approximately 5x10 6 intermediate erythroblasts staged using morphology and immunophenotyping were prepared for electron microscopy as previously described. 15 The percentage of nuclei with spongy heterochromatin was determined from large field images. Gels were fixed in 10% trichloroacetic acid and stained with the JB-2 staining system (Perkin Elmer, USA) as per manufacturer instructions.
Iso-electric
RNA isolation and gene expression analysis: 1-5x10 6 cells were fixed in 1 ml TRIreagent (Sigma), snap frozen on dry ice and stored at -80ºC. RNA was extracted by addition of 100 µl 1-bromo-3-chloropropane, separation in a Phase Lock gel Heavy tube (5Prime) and precipitation with 1 µl of GlycoBlue and an equal volume (~500 µl) isopropanol and centrifugation (10 min, 12,000 g, 4ºC Table 2 ).
Chromatin accessibility: ATAC-seq was performed as previously described 16, 17 using 0.7x10 5 cells and sequenced on the NextSeq platform (Illumina v2 chemistry) with 39-bp paired-end reads. Reads were mapped to the hg19 genome using NGseqBasic 18 (V20; --nextera --blacklistFilter --noWindow), which utilises Bowtie. 19 Sequence depth and mapped reads are provided (Supplemental Table   3 ). GEO repositories of sorted cell populations (GSE75384) were analysed by the same method. For visualisation PCR-duplicate filtered replicates were merged using Samtools 20 (v1.3) and converted to bigwig format with minimal smoothing using deepTools 21 Immunofluorescence: 1-2x10 5 cells were washed and allowed to settle on poly-Llysine treated coverslips for 5 min. Cells were fixed in 4% PFA for 15 min and permeabilised in 0.2% Triton X-100 in PBS for 10 min at RT. Slides were blocked using 10% fetal calf serum in PBS at RT for 30 min. Antibodies were prepared in blocking solution at the following concentrations: goat anti-GDF15 (ab-39999; Abcam 1/50) and donkey anti-goat Alexa488 (A-11055; Thermo Fisher Scientific 1/300). Coverslips were mounted in Vectashield with 1 µg ml -1 DAPI added as a nuclear counterstain.
Antibody labeling, barcoding and mass cytometry for CyTOF: Samples were prepared for CyTOF as previously described. 25 The antibody cocktail used for mass cytometry is shown in Supplemental Table 6 .
Mass cytometry data analyses: Files were processed following Fluidigm recommendations, including randomization and normalization using EQ Beads signal. Files were concatenated, de-barcoded and randomized according to Fluidigm instructions using the CyTOF ® Software. FCS files exported from the Helios machine were imported into FlowJo v10. 150,000 events were subsampled from each file (three healthy donors and three C15orf41 patients).
Subsampled events were then concatenated together for Uniform Manifold Approximation and Projection (UMAP). 26 Data availability: Sequencing data generated will be available on the Gene Expression Omnibus.
Results:
Peripheral blood-derived CD34 + cells can be differentiated through to erythroblast enucleation
A three-phase ex vivo culture system 8 was used to differentiate erythroid cells from CD34 + haematopoietic stem cells (HSCs) derived from peripheral blood of healthy donors ( Figure 1A ). In addition to the morphological assessment of cultured erythroblasts we characterised their chromatin landscape, globin gene expression profile and the expression of erythroid proteins and transcription factors, to comprehensively evaluate differentiation status. We observed a 1x10 4 fold expansion of erythroid cell numbers over the course of differentiation. Cellular morphology of normal donor derived cells from pro-erythroblasts to terminal differentiation is shown in Figure 1B . Immunophenotyping revealed a gain of glycophorin A (CD235a) and transferrin receptor (CD71), which typically occurred by day 7 ( Figure 1C ). As maturation progressed, cells visibly haemoglobinised by day 10 ( Figure 1D ) and this coincided with increasing expression of the adult globins ( Supplementary Figure 2A) , with the α-to β-globin ratios remaining around 1 throughout the differentiation (Supplemental Figure 2B ). Furthermore, IEF Figure 1C ). Enucleated cells were visible on cytospins at this stage ( Figure 1B) .
CDA-I patients
To date, ~56 mutations have been reported in CDAN1 and C15orf41, 1, 3, 4, 27 although no correlation has been reported between the different mutations within a gene and disease severity. Whilst CDA-I patients are characterised by macrocytic anaemia, 2 there can be differences in the severity of the disease between individuals, even in those with identical mutations. 28 We examined eight CDA-I patients in this study (Figure 2A ). Patients from our cohort (excluding those receiving regular blood transfusion or venesections) have haemoglobin (Hb) levels and mean cell volumes (MCV) within the normal range ( Figure 2B ), consistent with ~30% of clinical cases. 2 These patients do however tend to have higher mean cell haemoglobin (MCH), and a reduced red cell count (RBC) compared to healthy donors ( Figure 2B ). In one patient (UPID6) with CDA-I, confirmed by TEM, a potentially pathogenic homozygous mutation was identified in CDAN1 although the allele frequency for this mutation is >1% in specific populations. Data from this patient was included in the CDAN1 mutation group.
Differentiating erythroblasts from healthy donors and CDA-I patients appear broadly equivalent by immunophenotyping
We studied the expansion and differentiation of erythroblasts derived from CD34 + HSCs from CDA-I patients with a variety of mutations in the two known causative genes C15orf41 and CDAN1 (Figure 2A ) which became especially obvious in the later phase of culture ( Figure 4A ). Such expansion is indicative of ineffective erythropoiesis, which has been characterised as a proliferating pool of immature erythroid cells and sub-optimal production of mature erythroblasts. 30 Analysis of open chromatin regions can be used to distinguish cell types and deconvolve mixed cell populations; 11, 31 therefore to further compare our differentiating healthy and patient cells we assayed chromatin accessibility using ATAC-seq. 16 Figure 4D ). Elevated expression of growth differentiation factor 15 (GDF15), a marker of ineffective erythropoiesis, known to be elevated in serum from CDA-I patients 32 was also detected by immunofluorescence (IF) in ex vivo cultured erythroblasts from CDA-I patients (Supplementary Figure 5B) . Therefore, differentiation of CDA-I patient material ex vivo successfully recapitulates abnormal patient phenotypes, previously only reported in vivo.
Evidence of a Genotype/Phenotype Correlation in CDA-I
We next assessed the effects of patient mutations on the enucleation stage of differentiation. Firstly, analysis of cellular morphology indicated a persistence of erythroid precursors in CDA-I erythroblasts, particularly in those from patients with bi-allelic C15orf41 mutations, ( Figure 5A ), together with a significant reduction in the percentage of enucleated cells ( Figure 5B ). Levels of enucleation were reduced to a lesser extent in the patients with mutations in CDAN1 ( Figure 5B and Supplemental Figure 6B ). Secondly, immunophenotyping of cultured erythroblasts in the enucleation phase revealed changes in Band 3 expression in CDA-I patients ( Figure 3B and Supplemental Figure 3A ). In normal erythropoiesis Band 3 shows a dramatic increase from the pro-erythroblasts to late erythroblasts, 9 and while CDA-I patient erythroblasts did progressively gain Band 3, the level of protein was significantly less at day 17 than in healthy donors ( Figure 5C ). This supports other indications of a delay in the progression of differentiation in patient derived erythroblasts. Notably the Band 3 reduction was more severe in patients with C15orf41 mutations (n=3 P=0.0088) than in the CDAN1 mutant cells (n=4 P=0.0127) ( Figure 5D ), suggesting the existence of a genotype/phenotype correlation. 33
Cultured erythroblasts can be used to diagnose CDA-I
The pathognomic diagnostic finding for CDA-I until now has been identification of specific heterochromatin abnormalities in bone marrow biopsies by TEM. The ex vivo culture system described here was used to confirm the diagnosis of CDA-I in a patient with a mutation in CDAN1 (UPID16) without the need for an invasive bone marrow aspirate ( Figure 4C ). Instead, genetic analysis was conducted on the patient, who presented with unexplained anaemia, using the Oxford Red Cell Panel (ORCP) 34 to identify any potentially pathogenic mutation ( Figure 6 ). Following identification of a CDAN1 variant , CD34 + progenitors from UPID16 were extracted and grown in our differentiation system. After 11 days in culture TEM was conducted on the resulting intermediate erythroblasts and revealed 29% of erythroblasts with abnormal chromatin morphology, thus confirming diagnosis of CDA-I.
Discussion:
Erythropoiesis is a complex, multi-step process coupling cell division with differentiation, starting from a heterogeneous population of haematopoietic stem cells 35 and resulting in mature reticulocytes. 36 Here we demonstrate that this can be modeled in an ex vivo culture system with erythroblasts passing through the expected stages of differentiation with appropriate expression of erythroid cell surface markers. 9 By day 17 in our system approximately 70-80% of the cells were enucleated (Supplemental Figure 6B ) indicating that erythroid differentiation was able to reach completion. Further, we were able to recapitulate the cardinal clinical feature of CDA-I, where we show by TEM that up to 40% of cultured CDA-I erythroblasts have spongy heterochromatin. In agreement with reported clinical findings 32,37 we a l s o see high levels of the hepcidin suppression factor GDF15 in cultured erythroblasts from CDA-I patients, again indicating that our culture system recapitulates common features of CDA-I and can therefore be used to elucidate mechanisms underlying the ineffective erythropoiesis in this disease.
While ex vivo culture from HSCs reproduces aspects of normal erythropoiesis and provides a source of erythroid cells to study, a number of confounding factors have been identified that make interpretation of the data difficult. 14, 38 Therefore, in order to investigate differences between patient-derived erythroblasts and those from healthy controls we took extreme care to stage the cultures using an array of methods that included FACS and CyTOF, which both rely on immunophenotyping cell populations. While such methods showed healthy and diseased erythroblasts were immunologically similar during the expansion phase and into early differentiation, aspects of disordered erythropoiesis became evident after this time by several parameters. Chromatin accessibility is a preferred approach for cell type classification over other methods such as RNA-seq and has been used to characterise all the blood lineages from bone marrow in humans. 31 Further, it is well documented that subsets of regulatory elements are systematically activated and repressed to enable commitment to the different haematopoietic lineages and particularly during erythroid-megakaryocyte differentiation. 39 Therefore we chose to use ATAC-seq as a genome-wide method of staging the cells. When our samples were aligned with a defined ATAC-seq erythroid trajectory, 31 normal and patient material became clearly distinguishable indicating that CDA-I patients have a more precursor-like accessibility profile, with a disruption in progression through erythropoiesis leading to the reduced erythroid output we observe in CDA-I. In agreement, cytospins contained increased numbers of erythroid precursors and fewer enucleated cells. Although dysregulated Band 3 expression has been observed in MDS patients, 9 the abnormal expression of Band 3 that we report has not been previously described in CDA-I patients and aligns with our other observations of affected terminal differentiation.
In terminal erythropoiesis, erythroid progenitors have a rapid cell cycle with a close association between the number of cell divisions and differentiation in order to generate the correct numbers of terminal erythroblasts. 40 Proerythroblasts from umbilical cord CD34 + cells have been shown to have limited proliferative capacity through the successive stages to orthochromatic erythroblasts. 9 Importantly, defects in various cell cycle genes have been reported to result in anaemia. 41 Our data show, for the first time, increased proliferation of patient erythroblasts compared to healthy cells, which occurs in parallel with morphological and DNA accessibility differences that could impact on the closely coupled cell cycle progression and differentiation speed. Interestingly, expansion of the numbers of erythroid cell precursors, particularly the proerythroblasts, has been reported in ineffective erythropoiesis observed in patients with β-thalassemia. 30 Further it has been shown that the tight link between the number of cell divisions and differentiation can be uncoupled by treatment with glucocorticoids, thought to be acting on developmental regulatory proteins. 42 How this occurs in the case of CDA-I is not yet clear although previous findings from non-erythroid cell lines show Codanin-1 to be cell cycle regulated 7 and cause an increase in cell cycle rate if over-expressed. 5 The final stages of erythropoiesis involve chromatin and nuclear condensation prior to expulsion of the pyknotic nuclei by enucleation 36, 43 and this process is highly organized 44 with chromatin condensation playing an important role. 45 The abnormal spongy heterochromatin observed in CDA-I could have a significant impact on the usual processes that precede enucleation, such as the selective loss of histones.
Remarkably, a substantial number of erythroblasts progress to enucleation without developing the catastrophic changes in chromatin compaction and organisation apparent in spongy nuclei. This implies that the effects of the aberrant proteins must reach a threshold within individual cells to produce the pathognomic phenotype.
Recently it has been reported that two distinct types of CDA-I exist (CDA-Ia MIM 224120 and CDA-Ib MIM 615631). 33 The differential diagnosis is based on the levels of Hb and MCV, with the CDA-Ib patients (caused by C15orf41 mutations) thought to be more severely affected, although the haematological data of our patient cohort ( Figure 2B) shows there is overlap between the blood indices in CDA-I patients (excluding those regularly transfused or venesected) irrespective of the mutation. However, using our culture system, we observe an enucleation defect and significantly reduced levels of Band 3 expression in late erythroblasts from C15orf41 patients, as compared to those with mutations in CDAN1. This suggests that there may indeed be a distinction based on patient genotype and further that the CDA-I phenotype may be more severe when arising from C15orf41 mutations. analysis to confirm and improve the rate and accuracy of diagnosis of CDA-I. 34 However the pathogenicity of novel C15orf41 or CDAN1 variants identified cannot be determined without further evidence. We propose that the ex vivo culture system reported here can be used for such validation, as we have clearly shown the pathognomic feature of spongy heterochromatin in our cultured erythroblasts which would enable a diagnosis of CDA-I to be made from peripheral blood.
Benefits include avoidance of invasive bone marrow aspirates and associated risks, 46 as well as precise diagnosis for patients who have often had many years of clinical investigation. 34 Ultimately this could streamline the diagnosis pathway and improve care for patients with this rare genetic form of anaemia, as well as providing patient-specific erythroblasts for research.
In this study we provide a detailed characterisation of CDA-I patient-specific erythroblasts, which have been modeled ex vivo. Results show that we can recapitulate aspects of the disease pathology seen in CDA-I, including high levels of cells with spongy heterochromatin as well as increased GDF15 expression. We also report here for the first time that CDA-I patient erythroblasts have elevated levels of proliferation, together with persistence of erythroid precursors. The abnormalities identified during late erythropoiesis in Band 3 expression and levels of enucleation most markedly affect patients with mutations in C15orf41, providing firm evidence for a genotype/phenotype correlation in CDA-I.
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